Reduction Of Frown Lines - Mentor Corporation Announces Completion Of PurTox(R) 3A Study
Oct 3rd 2008Drug InformationClinical Trials
Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetic market, today announced completion of the first of three Phase 3 clinical trials with its purified botulinum Type A neurotoxin (PurTox®) for the reduction of glabellar rhytides (frown lines). This newly completed study involved 400 subjects at ten investigational sites in the United States. Subjects received a single treatment with PurTox or placebo.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
